OncoMed Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results

Published: Nov 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results and recent corporate events for the quarter ended September 30, 2013. For the third quarter of 2013, OncoMed reported total revenue of $12.9 million and a net loss of $3.5 million, or $0.15 per share. As of September 30, 2013, OncoMed's cash, cash equivalents and marketable securities totaled $128.6 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news